Cargando…
IL‐7 is expressed in malignant mesothelioma and has a prognostic value
Malignant pleural mesothelioma (MPM) is an aggressive cancer mainly related to asbestos exposure. Despite recent therapeutic advances, notably immunotherapies, the benefit remains limited and restricted to a small percentage of patients. Thus, a better understanding of the disease is needed to ident...
Autores principales: | Mai, Hoa‐Le, Deshayes, Sophie, Nguyen, Thi‐Van‐Ha, Dehame, Virginie, Chéné, Anne‐Laure, Brouard, Sophie, Blanquart, Christophe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580880/ https://www.ncbi.nlm.nih.gov/pubmed/36054746 http://dx.doi.org/10.1002/1878-0261.13310 |
Ejemplares similares
-
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma
por: Bensaid, Douae, et al.
Publicado: (2018) -
Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma
por: Blondy, Thibaut, et al.
Publicado: (2020) -
Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis
por: Smeele, Patrick, et al.
Publicado: (2018) -
The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
por: Blanquart, Christophe, et al.
Publicado: (2020) -
Editorial: Focus on malignant pleural mesothelioma immunology and immunotherapy
por: Porta, Chiara, et al.
Publicado: (2023)